

Mattia Galli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9052590/mattia-galli-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56
papers

846
citations

14
h-index

28
g-index

69
ext. papers

1,323
ext. citations

5.5
avg, IF

4.29
L-index

#	Paper	IF	Citations
56	Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2015 , 36, 1377-84	9.5	161
55	Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. <i>European Heart Journal</i> , 2012 , 33, 2928-38	9.5	78
54	Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: a 3-vessel optical coherence tomography study. <i>American Heart Journal</i> , 2014 , 167, 59-67	4.9	57
53	Coronary Atherosclerotic Phenotype and Plaque Healing in Patients With Recurrent Acute Coronary Syndromes Compared With Patients With Long-term Clinical Stability: An In Vivo Optical Coherence Tomography Study. <i>JAMA Cardiology</i> , 2019 , 4, 321-329	16.2	55
52	Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study. <i>Journal of Cardiovascular Medicine</i> , 2008 , 9, 1004-10	1.9	49
51	A current approach to heart failure in Duchenne muscular dystrophy. <i>Heart</i> , 2017 , 103, 1770-1779	5.1	47
50	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019 , 16, 113-130	14.8	37
49	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Physiology</i> , 2019 , 10, 1347	4.6	36
48	Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. <i>Lancet, The</i> , 2021 , 397, 1470-1483	40	32
47	Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 105-116	6.4	25
46	Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. <i>Europace</i> , 2020 , 22, 538-546	3.9	21
45	Eosinophil cationic protein and clinical outcome after bare metal stent implantation. <i>Atherosclerosis</i> , 2011 , 215, 166-9	3.1	21
44	Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 86-93	6.4	18
43	Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 43-56	6.4	16
42	Where Does Inflammation Fit?. <i>Current Cardiology Reports</i> , 2017 , 19, 84	4.2	14
41	Optical coherence tomography assessment and quantification of intracoronary thrombus: Status and perspectives. <i>Cardiovascular Revascularization Medicine</i> , 2015 , 16, 172-8	1.6	14
40	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	14

39	Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 128-129	6.4	13
38	Association between inflammatory biomarkers and in-stent restenosis tissue features: an Optical Coherence Tomography Study. <i>European Heart Journal Cardiovascular Imaging</i> , 2014 , 15, 917-25	4.1	12
37	Electronic Cigarettes and Cardiovascular Risk: Caution Waiting for Evidence. <i>European Cardiology Review</i> , 2019 , 14, 151-158	3.9	11
36	Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug eluting stent implantation: a network Meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	8
35	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.. <i>European Heart Journal</i> , 2021 ,	9.5	8
34	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 963-978	3.8	8
33	Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. <i>IJC Heart and Vasculature</i> , 2020 , 28, 100524	2.4	6
32	Stent Thrombosis With Dual Antithrombotic Therapy in Atrial Fibrillation-ACS/PCI Trials. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1727-1728	15.1	6
31	High-risk percutaneous coronary intervention: how to define it today?. <i>Minerva Cardioangiologica</i> , 2018 , 66, 576-593	1.1	6
30	Early anticoagulation in the current management of NSTEMI-ACS: Evidence, guidelines, practice and perspectives. <i>International Journal of Cardiology</i> , 2019 , 275, 39-45	3.2	6
29	Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 55-56	6.4	6
28	Safety and efficacy of P2Y inhibitor monotherapy in patients undergoing percutaneous coronary interventions. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 9-21	4.1	6
27	Dual quantitative coronary angiography accurately quantifies intracoronary thrombotic burden in patients with acute coronary syndrome: Comparison with optical coherence tomography imaging. <i>International Journal of Cardiology</i> , 2019 , 292, 25-31	3.2	5
26	Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 154, 103074	7	5
25	Optimal P2Y12 inhibition in older adults with acute coronary syndromes: A network meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	5
24	Antiplatelet therapy after percutaneous coronary intervention.. <i>EuroIntervention</i> , 2022 , 17, e1371-e1396	9.1	5
23	Are Atherogenic Lipoprotein Phenotype and Inflammation Indicative of Plaque Phenotype and Clinical Stability in Coronary Artery Disease?-Reply. <i>JAMA Cardiology</i> , 2019 , 4, 951-952	16.2	4
22	Colchicine in ischemic heart disease: the good, the bad and the ugly. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1531-1542	6.1	4

21	Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	4
20	Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 1273-1285	5.5	4
19	Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. <i>ESC Heart Failure</i> , 2019 , 6, 884-888	3.7	3
18	Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation. <i>Advances in Therapy</i> , 2021 , 38, 2891-2907	4.1	2
17	ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrlal fibrillation: the (ORIGAMI) study. <i>Journal of Cardiovascular Medicine</i> , 2021 , 22, 175-179	1.9	1
16	Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: not a matter of faith. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e16-e17	6.4	1
15	Role of perilipin 2 in microvascular obstruction in patients with ST-elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 633-642	4.3	1
14	Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3690-3698	3.8	1
13	Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials. <i>Current Opinion in Cardiology</i> , 2021 , 36, 390-396	2.1	1
12	A case of resistant thrombus: all you can hit in very late stent thrombosis. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 397-399	1.9	1
11	The Role of Antiplatelet Therapy in Patients With MINOCA.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 821297	5.4	1
10	Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 3231-3232	15.1	0
9	Response-letter to the editor: colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e72-e73	6.4	0
8	How deep is your lesion? Extreme guideliner V3 intubation through RIMA graft to treat a distal left anterior descending artery stenosis. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19, 606-608	1.9	0
7	Dabigatran-based dual antithrombotic therapy for patients with atrial fibrillation and ST-elevation myocardial infarction undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , 2021 , 17, 443-444	3.1	0
6	Type 2 myocardial infarction: a diagnostic and therapeutic challenge in contemporary cardiology.. <i>Internal and Emergency Medicine</i> , 2022 , 17, 317	3.7	0
5	Recurrent chest pain: what is essential is invisible to the eye? <i>European Heart Journal Supplements</i> , 2019 , 21, C11-C14	1.5	
4	Radial versus femoral and bivalirudin versus unfractionated heparin in vulnerable patients with acute coronary syndromes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 874-876	0.7	

- 3 Recurrence of angina after ST-segment elevation myocardial infarction: the role of coronary microvascular obstruction. *European Heart Journal: Acute Cardiovascular Care*, **2019**, 2048872619880661^{4.3}
- 2 Aspirin in primary prevention of cardiovascular disease in the elderly. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2020**, 6, 326-327 6.4
- 1 Acceso radial frente a femoral y bivalirudina frente a heparina no fraccionada en pacientes vulnerables con síndrome coronario agudo. *Revista Española De Cardiología*, **2020**, 73, 874-876 1.5